{"id":"W4283775908","doi":"10.1016/j.annonc.2022.06.011","title":"Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Hazard ratio; Internal medicine; Placebo; Chemotherapy; Oncology; Ovarian cancer; Population; Cohort; Surgery; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262442,0.0002280737,0.0008290852,0.0001755562,0.0001380305,0.000004450422,0.0002592194,0.0001139383,0.000255665],"category_scores_gemma":[0.0002307936,0.0001560628,0.0003124712,0.000424481,0.0003977677,0.00004092945,0.00005412014,0.0002983584,4.531437e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003543328,"about_ca_system_score_gemma":0.001238341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001480169,"about_ca_topic_score_gemma":0.00004230331,"domain_scores_codex":[0.9975396,0.0003536134,0.0007654672,0.0003584034,0.0005801313,0.0004028284],"domain_scores_gemma":[0.9969072,0.0005277395,0.001227757,0.0004157188,0.0008362121,0.00008533982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9072874,0.004177757,0.0008040537,0.0001068998,0.001086526,0.000004144519,0.001299471,0.0005034569,0.01118887,0.0001347843,0.002723767,0.07068288],"study_design_scores_gemma":[0.6179365,0.1381766,0.01430952,0.0006615984,0.0005381283,0.000008072846,0.0004833073,0.000189064,0.1947413,0.000136053,0.03243208,0.0003877446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875404,0.000318244,0.00002071294,0.007025946,0.001220072,0.003037769,0.0005723064,0.00001942869,0.0002451777],"genre_scores_gemma":[0.9974011,0.0001708182,0.0003189157,0.001090439,0.0002017234,0.0006224997,0.0001069448,0.00004117376,0.00004640691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2893509,"threshold_uncertainty_score":0.6364054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1289920043521299,"score_gpt":0.4438730939755801,"score_spread":0.3148810896234502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}